The Uromigos
By The Uromigos
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by The Uromigos
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 4
Reviews: 0
Episodes: 441
Description
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
| Episode | Date |
|---|---|
|
Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer
|
Oct 08, 2025 |
|
Episode 443: ESMO 2025 Bladder Cancer Preview
|
Oct 02, 2025 |
|
Episode 441: The History of IO in Urothelial Cancer - Part 2
|
Sep 29, 2025 |
|
Episode 440: The History of IO in Urothelial Cancer - Part 1
|
Sep 22, 2025 |
|
Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer
|
Sep 15, 2025 |
|
Episode 438: The History of Testis Cancer Treatment
|
Sep 08, 2025 |
|
Episode 437: Uromigos Japan - バルバーサ (Erdafitinib)を実臨床でどう使うか！
|
Sep 01, 2025 |
|
Episode 436: The History of IO in RCC - Part 2
|
Aug 25, 2025 |
|
Episode 435: The History of IO in RCC - Part 1
|
Aug 18, 2025 |
|
Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC
|
Aug 04, 2025 |
|
Episode 433: Uromigos Japan - 改訂版ASCO mCRPCガイドライン
|
Aug 01, 2025 |
|
Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap
|
Jul 21, 2025 |
|
Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials
|
Jul 14, 2025 |
|
Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers?
|
Jul 07, 2025 |
|
Episode 429: ASCO2025レポート
|
Jul 02, 2025 |
|
Episode 428: ASCO 2025 Recap
|
Jun 16, 2025 |
|
Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC)
|
Jun 13, 2025 |
|
Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC
|
Jun 06, 2025 |
|
Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI
|
Jun 04, 2025 |
|
Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session
|
Jun 02, 2025 |
|
Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC
|
Jun 01, 2025 |
|
Episode 422: ACSO 2025 - ctDNA data from NIAGARA
|
Jun 01, 2025 |
|
Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer
|
Jun 01, 2025 |
|
Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer
|
Jun 01, 2025 |
|
Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study
|
May 31, 2025 |
|
Episode 418: ASCO 2025 - Biomarkers in RCC
|
May 31, 2025 |
|
Episode 417: ASCO25 GUの注目演題について3人でDiscussion！！
|
May 24, 2025 |
|
Episode 416: ASCO 2025 Preview
|
May 19, 2025 |
|
Episode 415: Uromigos Score 前立腺がん編
|
May 12, 2025 |
|
Episode 414: Uromigos score en cáncer de próstata metastasico - más allá de las guías clínicas
|
May 12, 2025 |
|
Episode 413: The Uromigos Score for Advanced Prostate Cancer
|
May 12, 2025 |
|
Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC
|
May 05, 2025 |
|
Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMUIBC from SunRISe-1
|
May 05, 2025 |
|
Episode 411: Live from EIKCS in Amsterdam - RCC Highlights
|
May 03, 2025 |
|
Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC
|
Apr 26, 2025 |
|
Episode 408: Uromigos Japan - European Delphi Study of mRCCについてdiscussion
|
Apr 23, 2025 |
|
Episode 407: Drug Development in China: Part 2 of 2
|
Apr 21, 2025 |
|
Episode 406: Drug Development in China: Part 1 of 2
|
Apr 14, 2025 |
|
Episode 405: The Good News About Cancer podcast
|
Apr 11, 2025 |
|
Episode 404: 177 Lu-PSMA Pre-chemotherapy in mCRPC. Final Podcast from the Canary Islands
|
Apr 07, 2025 |
|
Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands
|
Apr 02, 2025 |
|
Episode 402: Uromigos en Espanol: Futuro del carcinoma de células renales
|
Mar 31, 2025 |
|
Episode 401: ADCs in Bladder Cancer. Part 1 from the Canary Islands
|
Mar 29, 2025 |
|
Episode 400: The Uromigos Score for Urothelial Cancer
|
Mar 28, 2025 |
|
Episode 399: A PD1/VEGF Bispecific in Lung Cancer - Lessons for GU Cancers?
|
Mar 24, 2025 |
|
Episode 398: Reflections on the Felix Feng Symposium at ASCO GU
|
Mar 17, 2025 |
|
Episode 397: APCCC Diagnostics Conference recap
|
Mar 10, 2025 |
|
Episode 396: Uromigos Japan - 激論 @JSMO25
|
Mar 09, 2025 |
|
Episode 395: Uromigos Japan: ASCO GU 2025のレビュー
|
Mar 03, 2025 |
|
Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025
|
Mar 01, 2025 |
|
Episode 393: ASCO GU 2025 Review Podcast
|
Feb 26, 2025 |
|
Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC
|
Feb 15, 2025 |
|
Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214
|
Feb 15, 2025 |
|
Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update
|
Feb 15, 2025 |
|
Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer
|
Feb 15, 2025 |
|
Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results
|
Feb 14, 2025 |
|
Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes
|
Feb 14, 2025 |
|
Episode 386: ASCO GU 2025 - APRI Meta-analysis
|
Feb 13, 2025 |
|
Episode 385: ASCO GU 2025 - TALAPRO-2
|
Feb 13, 2025 |
|
Episode 384: ASCO GU Preview
|
Feb 06, 2025 |
|
Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC
|
Feb 05, 2025 |
|
Episode 382: Uromigos Japan - TROPICs-04の考察
|
Feb 05, 2025 |
|
Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
|
Jan 27, 2025 |
|
Episode 380: The Role of SBRT in RCC
|
Jan 13, 2025 |
|
Episode 379: Uromigos Japan: 2024年のGU Oncologyを振り返る
|
Jan 10, 2025 |
|
Episode 378: 2025 Preview of Important GU Data
|
Jan 06, 2025 |
|
Episode 375: Renal Cancer 2024 Highlights
|
Dec 23, 2024 |
|
Episode 376: Bladder Cancer 2024 Highlights
|
Dec 23, 2024 |
|
Episode 377: Prostate Cancer 2024 Highlights
|
Dec 23, 2024 |
|
Episode 374: Mechanisms of HIF Resistance
|
Dec 18, 2024 |
|
Episode 373: KEYNOTE-564 Asian OSとANNARの解説
|
Dec 11, 2024 |
|
Episode 372: FDA Accelerated Approval Process
|
Dec 09, 2024 |
|
Episode 371: TROPICS-04 Results from ESMO Asia
|
Dec 07, 2024 |
|
Episode 370: Artificial Intelligence in Medical Oncology
|
Dec 02, 2024 |
|
Episode 369: Paper of the Month with Bishoy Faltas
|
Nov 25, 2024 |
|
Episode 368: Radiomics in RCC: Live from IKCS
|
Nov 19, 2024 |
|
Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer
|
Nov 11, 2024 |
|
Episode 366: ARPIs in Prostate Cancer - Are They Different?
|
Nov 04, 2024 |
|
Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC)
|
Oct 28, 2024 |
|
Episode 364: 腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜
|
Oct 24, 2024 |
|
Episode 363: 前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
|
Oct 24, 2024 |
|
Episode 362: 膀胱がんの最新の話題〜周術期薬物療法とADC〜
|
Oct 24, 2024 |
|
Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer
|
Oct 22, 2024 |
|
Episode 360: The SUNRISE Program in Bladder Cancer
|
Oct 15, 2024 |
|
Episode 359: #UromigosLive24 - IO after IO in RCC
|
Oct 09, 2024 |
|
Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville
|
Sep 30, 2024 |
|
Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer
|
Sep 30, 2024 |
|
Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC
|
Sep 28, 2024 |
|
Episode 355: #UromigosLive24 - Radioligands in prostate cancer
|
Sep 28, 2024 |
|
Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer
|
Sep 28, 2024 |
|
Episode 353: #UromigosLive24 ADC session
|
Sep 28, 2024 |
|
Episode 352: ESMO 2024 - RCC and Bladder review
|
Sep 23, 2024 |
|
Episode 351: ESMO 2024 review part 1: prostate cancer
|
Sep 21, 2024 |
|
Episode 350: ESMO 2024 - NIAGARA
|
Sep 16, 2024 |
|
Episode 349: ESMO 2024 - Uromigos Japan!!
|
Sep 16, 2024 |
|
Episode 348: ESMO 2024 - UpFrontPSMA
|
Sep 15, 2024 |
|
Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer
|
Sep 15, 2024 |
|
Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC
|
Sep 14, 2024 |
|
Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC
|
Sep 14, 2024 |
|
Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC
|
Sep 14, 2024 |
|
Episode 343: ESMO 2024 - TiNivo-2 Trial
|
Sep 14, 2024 |
|
Episode 342: ESMO 2024 Preview with Silke Gillessen
|
Sep 03, 2024 |
|
Episode 341: Hormone Resistance in Prostate Cancer
|
Aug 27, 2024 |
|
Episode 340: Cancer Immunity Cycle Update
|
Aug 19, 2024 |
|
Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU
|
Aug 09, 2024 |
|
Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More
|
Aug 06, 2024 |
|
Episode 337: Updated NCCN Guidelines in RCC
|
Jul 30, 2024 |
|
Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer
|
Jul 24, 2024 |
|
Episode 335: Novel immune therapies for renal cancer
|
Jul 19, 2024 |
|
Episodio 334 en español: Tres Uramigas ASCO 2024
|
Jul 11, 2024 |
|
Episode 333: The Uromigos Cup - The Netherlands
|
Jul 05, 2024 |
|
Episode 332: The Uromigos Cup - Germany's Entry
|
Jun 26, 2024 |
|
Episode 331: AUA 2024 NMIBC Highlights
|
Jun 21, 2024 |
|
Episode 330: ASCO 2024 Highlights
|
Jun 10, 2024 |
|
Episode 329: Japan in the Uromigos Cup qualifying round
|
Jun 07, 2024 |
|
Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies
|
Jun 05, 2024 |
|
Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates
|
Jun 04, 2024 |
|
Episode 326 ASCO24: KIM-1 in Renal Cancer
|
Jun 03, 2024 |
|
Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer
|
Jun 03, 2024 |
|
Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC
|
Jun 02, 2024 |
|
Episode 323 ASCO24: TDXD in Bladder Cancer
|
Jun 02, 2024 |
|
Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)
|
Jun 02, 2024 |
|
Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?
|
Jun 01, 2024 |
|
Episode 320: Team Canada's entry for the Uromigos Cup
|
May 25, 2024 |
|
Episode 319: ASCO 2024: A Preview of GU Data
|
May 19, 2024 |
|
Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases
|
May 13, 2024 |
|
Episode 317: AUA 2024 Preview with the AUA Secretary
|
May 01, 2024 |
|
Episode 316: APCCC 2024 Summary with Silke Gillessen
|
Apr 28, 2024 |
|
Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer
|
Apr 27, 2024 |
|
Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer
|
Apr 27, 2024 |
|
Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease
|
Apr 26, 2024 |
|
Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer
|
Apr 26, 2024 |
|
Episode 311: The Uromigos Paper of the Month - The POUT Trial
|
Apr 23, 2024 |
|
Episode 310: Dosing and duration of drugs from a cost perspective
|
Apr 17, 2024 |
|
Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer
|
Apr 07, 2024 |
|
Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy
|
Apr 07, 2024 |
|
Episode 307: Bladder-Sparing Approaches Part 2
|
Apr 02, 2024 |
|
Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC
|
Mar 28, 2024 |
|
Episode 305: FDA and Oncology Clinical Trials
|
Mar 19, 2024 |
|
Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC
|
Mar 11, 2024 |
|
Episode 303: Community GU Oncology
|
Mar 05, 2024 |
|
Episode 302: Part 2- Adjuvant Therapy in solid tumors
|
Feb 25, 2024 |
|
Episode 301: Cancer research from a global perspective.
|
Feb 20, 2024 |
|
Episode 300: Adjuvant PD1 Therapy in Solid Tumours
|
Feb 11, 2024 |
|
Episode 299: Androgen receptor ligand-directed degrader BMS-986365
|
Feb 07, 2024 |
|
Episode 298: ASCO GU 2024 Highlights
|
Jan 31, 2024 |
|
Episode 297: ASCO GU 2024: CONTACT2 Part 2 - The Aftermath
|
Jan 30, 2024 |
|
Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan
|
Jan 27, 2024 |
|
Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer
|
Jan 27, 2024 |
|
Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer
|
Jan 27, 2024 |
|
Episode 293: ASCO GU 2024: BRCAaway and CONTACT2
|
Jan 26, 2024 |
|
Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer
|
Jan 26, 2024 |
|
Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer
|
Jan 25, 2024 |
|
Episode 290: ASCO GU 2024 Preview
|
Jan 17, 2024 |
|
Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine
|
Jan 15, 2024 |
|
Episode 288: APCCC #3: Controversies around Radiotherapy
|
Jan 10, 2024 |
|
Episode 287 APCCC: Early Discontinuation of Therapy in HSPC
|
Jan 04, 2024 |
|
Episode 286: APCCC Prostate Cancer Meeting Overview
|
Jan 03, 2024 |
|
Episode 285: Holiday Special: Renal Cancer in 2023
|
Dec 22, 2023 |
|
Episode 284: Tres amigas: Lo más destacado del cáncer en urología en 2023
|
Dec 21, 2023 |
|
Episode 283: Holiday Special: Prostate Cancer in 2023
|
Dec 20, 2023 |
|
Episode 282: Holiday Special: Bladder Cancer in 2023
|
Dec 13, 2023 |
|
Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer
|
Dec 08, 2023 |
|
Episode 280: IKCS 2023 Overview
|
Nov 16, 2023 |
|
An apology
|
Nov 13, 2023 |
|
Episode 279: Management of IO-resistant RCC at #UromigosLive 2023
|
Nov 06, 2023 |
|
Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023
|
Nov 04, 2023 |
|
Episode 277: NMIBC Discussion at #UromigosLive 2023
|
Nov 04, 2023 |
|
Episode 276: ESMO 2023 Highlights
|
Oct 28, 2023 |
|
Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville
|
Oct 27, 2023 |
|
Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise
|
Oct 27, 2023 |
|
Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC
|
Oct 26, 2023 |
|
Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer
|
Oct 22, 2023 |
|
Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer
|
Oct 22, 2023 |
|
Episode 270: ESMO 2023 - Belzutifan in renal cancer
|
Oct 21, 2023 |
|
Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC
|
Oct 21, 2023 |
|
Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett
|
Oct 20, 2023 |
|
Episode 267: ESMO preview - things to look out for at the meeting
|
Oct 11, 2023 |
|
Episode 266: Radiotherapy for prostate cancer
|
Oct 10, 2023 |
|
Episode 265: Brachytherapy with Jeff Michalski
|
Oct 03, 2023 |
|
Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial
|
Sep 27, 2023 |
|
Episode 263: Toni Choueiri and papillary renal cancer
|
Sep 20, 2023 |
|
Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC.
|
Sep 12, 2023 |
|
Episode 261: part 2 ctDNA in bladder cancer
|
Sep 04, 2023 |
|
Episode 260: Celeste Simon: how to make a career in translation science work.
|
Aug 30, 2023 |
|
Episode 259: Cystectomy for bladder cancer
|
Aug 24, 2023 |
|
Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1
|
Aug 15, 2023 |
|
Episode 257: Chana Weinstock from the FDA
|
Aug 07, 2023 |
|
Episode 256: ctDNA in urothelial studies.
|
Jul 27, 2023 |
|
Episode 255: How to get an academic paper accepted
|
Jul 26, 2023 |
|
Episode 254: New RCC studies at KCRS 2023 with Laurence Albiges
|
Jul 17, 2023 |
|
Episode 253: Patients' perspectives on adjuvant and 1st line RCC
|
Jul 13, 2023 |
|
Episode 252: Talazoparib and its FDA approval in CRPC
|
Jul 04, 2023 |
|
Episode 251: Final part of VEGF/TKI vs IPI/NIVO discussion
|
Jun 26, 2023 |
|
Episode 250: Bob Motzer discusses IPI/Nivo vs VEGF/PD1
|
Jun 18, 2023 |
|
Episode 249: ASCO 2023 emergency podcast IPI/NIVO vs VEGF/PD1 in kidney cancer
|
Jun 18, 2023 |
|
Episode 248: ASCO23 GU highlights
|
Jun 14, 2023 |
|
Episode 246: ASCO 2023: EV pembro and erdafitinib +/- cetrelimab in 1st line UC
|
Jun 05, 2023 |
|
Episode 245: ASCO 2023 - CONTACT-03 cabozantinib +/- atezolizumab in renal cancer
|
Jun 05, 2023 |
|
Episode 244: ASCO 2023 PEACE-1 in CRPC
|
Jun 05, 2023 |
|
Episode 243: ASCO 2023 TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide
|
Jun 05, 2023 |
|
Episode 242: ASCO 2023 THOR study - erdafitinib vs chemo in bladder cancer
|
Jun 05, 2023 |
|
Episode 241: Statistics for clinical trials
|
Jun 01, 2023 |
|
Episode 240: Preview of GU Cancer at ASCO 2023
|
May 30, 2023 |
|
Episode 239: The STAMPEDE trial
|
May 22, 2023 |
|
Episode 238: Paper of the month: Biomarkers for neoadjuvant PD(L)1 therapy
|
May 14, 2023 |
|
Episode 237: 2023 AUA Highlights
|
May 09, 2023 |
|
Episode 236: ODAC for olaparib
|
May 02, 2023 |
|
Episode 235: Danny Heng and the IMDC classification in renal cancer
|
Apr 24, 2023 |
|
Episode 234: Amar Kishan, MD, on Neoadjuvant or Adjuvant Radiotherapy for Prostate Cancer
|
Apr 19, 2023 |
|
Episode 233: Destaques da 14ª reunião internacional brasileira de câncer urológico
|
Apr 15, 2023 |
|
Episode 232: Belzutifan in early and late renal cancer
|
Apr 14, 2023 |
|
Episode 231: Ursula Vogl, MD in the Rising Star Series
|
Apr 05, 2023 |
|
Episode 230: FGFR Inhibition in NMIBC With Sia Daneshmand
|
Mar 28, 2023 |
|
Episode 229: Kala Sridhar, MD on PET in Early Bladder Cancer
|
Mar 20, 2023 |
|
Episode 228: Karine Tawagi, MD in the Rising Star Series
|
Mar 15, 2023 |
|
Episode 227: 2023 ASCO GU Bladder Highlights and Paper of the Month with Michiel Van der Heijden
|
Mar 06, 2023 |
|
Episode 226: 2023 ASCO GU Prostate and RCC Highlights With Dan George
|
Feb 27, 2023 |
|
Episode 225: ASCO GU 2023: Brian Shuch, MD discusses the ZIRCON Phase III Study of girentuximab PET/CT imaging in RCC
|
Feb 20, 2023 |
|
Episode 224: ASCO GU 2023: discussing miR371 for Germ Cell Tumors with Christian Kollmannsberger
|
Feb 20, 2023 |
|
Episode 223: ASCO GU 2023: Discussing KEYNOTE-057 with Andrea Necchi, MD
|
Feb 17, 2023 |
|
Episode 222: ASCO GU 2023: New Data From IMvigor130 with Enrique Grande, MD
|
Feb 17, 2023 |
|
Episode 221: ASCO GU 2023: Matt Galsky, MD Gives an Update on the CheckMate 274 Trial
|
Feb 17, 2023 |
|
Episode 220: ASCO GU 2023: Discussing PARPi for CRPC with Michael Morris, MD
|
Feb 17, 2023 |
|
Episode 219: ASCO GU 2023: Neeraj Agarwal, MD, FASCO Discusses the TALAPRO-2 study
|
Feb 17, 2023 |
|
Episode 218: Discussing The Cost of Cancer Drugs With Daniel Goldstein, MD
|
Feb 07, 2023 |
|
Episode 217: Rising Star: Vadim Koshkin and ADCs
|
Feb 03, 2023 |
|
Episode 216: ADCs in Bladder Cancer With Petros Grivas, MD, PhD
|
Jan 30, 2023 |
|
Episode 215: Resumen cáncer de próstata y vejiga reunión Canarias
|
Jan 21, 2023 |
|
Episode 214: Resumen de la reunión en las Islas Canarias sobre cáncer renal
|
Jan 21, 2023 |
|
Episode 213: IL-15RaFc superagonist in NMIBC
|
Jan 09, 2023 |
|
Episode 212: What's coming in GU Cancers in 2023
|
Jan 02, 2023 |
|
Episode 211: CAR-T cell therapy in RCC
|
Dec 29, 2022 |
|
Episode 210: Christmas Prostate Cancer Debate - olaparib and abiraterone in selected or unselected patients
|
Dec 22, 2022 |
|
Episode 209: Christmas Bladder Cancer Debate - Cisplatin vs carboplatin in bladder cancer
|
Dec 17, 2022 |
|
Episode 208: Christmas Kidney Cancer Debate - Ipilimumab in renal cancer
|
Dec 12, 2022 |
|
Episode 207: Editorial on COSMIC-313
|
Dec 05, 2022 |
|
Episode 206: Dan Shapiro in the Rising Star series
|
Nov 28, 2022 |
|
Episode 205: Paper of the Month - Nab-paclitaxel and pembrolizumab in bladder cancer
|
Nov 21, 2022 |
|
Episode 204: Scott Haake in the Rising Star series
|
Nov 14, 2022 |
|
Episode 203: Renee Saliby in the Rising Star series
|
Nov 14, 2022 |
|
Episode 202: The Uromigos Paper of the Month - Docetaxel with or without continuous enza in CRPC
|
Nov 07, 2022 |
|
Episode 201: PARPi in CRPC
|
Nov 01, 2022 |
|
Episode 200: Chromophobe renal cancer
|
Oct 25, 2022 |
|
Episode 199: The Uromigos Paper of the Month - FGFR inhibition in bladder cancer
|
Oct 17, 2022 |
|
Episode 198: The RADICALS trial in prostate cancer
|
Oct 07, 2022 |
|
Episode 197: The Uromigos Nashville 2022
|
Sep 29, 2022 |
|
Episode 196: The COSMIC-313 Trial cabo/ipi/nivo in 1st line renal cancer
|
Sep 14, 2022 |
|
Episode 195 ESMO 2022: EV Pembrolizumab in 1st line bladder cancer
|
Sep 13, 2022 |
|
Episode 194 ESMO 2022: Pegylated il-2 + nivolumab in renal cancer
|
Sep 12, 2022 |
|
Episode 193 ESMO 2022: PRESTO - a phase III trial of androgen annihilation in biochemically relapsed prostate cancer
|
Sep 11, 2022 |
|
Episode 192 ESMO 2022: Summary of ESMO Adjuvant RCC Trials
|
Sep 11, 2022 |
|
Episode 191 ESMO 2022: PROSPER study of neoadjuvant nivolumab in RCC
|
Sep 10, 2022 |
|
Episode 190: ESMO 2022 Preview
|
Sep 02, 2022 |
|
Episode 189: The Uromigos Paper of the Month - Robotic vs open cystectomy
|
Aug 22, 2022 |
|
Episode 188: The 1st Uromigos Live and Unplugged face-to-face meeting
|
Aug 15, 2022 |
|
Episode 187: Cora Sternberg - The Uromigos Legends Series
|
Aug 15, 2022 |
|
Episode 186: Bernard Escudier - The Uromigos Legends Series
|
Aug 10, 2022 |
|
Episode 185: The Uromigos Paper of the Month - ctDNA in prostate cancer
|
Aug 01, 2022 |
|
Episode 184: Active surveillance in prostate cancer and the seeds of doubt
|
Jul 26, 2022 |
|
Episode 183: Oliver Sartor - The Uromigos Legends Series
|
Jul 18, 2022 |
|
Episode 182: ASCO Kidney Cancer Guidelines
|
Jul 11, 2022 |
|
Episode 181: Relapsed Germ Cell Tumours
|
Jun 27, 2022 |
|
Episode 180: Enzalutamide vs active surveillance in early prostate cancer
|
Jun 20, 2022 |
|
Episode 179: PSMA PET for Lutetium-177 in prostate cancer
|
Jun 20, 2022 |
|
Episode 178: ASCO 2022: Germline variants in men of African descent with prostate cancer
|
Jun 07, 2022 |
|
Episode 177: ASCO 2022: ENZAMET survival update
|
Jun 05, 2022 |
|
Episode 176: ASCO 2022: HER-2 ADCs in Bladder Cancer
|
Jun 05, 2022 |
|
Episode 175: ASCO 2022: Targeting the microbiome in renal cancer
|
Jun 04, 2022 |
|
Episode 174: ASCO 2022: Cell free DNA as a biomarker in bladder cancer
|
Jun 03, 2022 |
|
Episode 173: ASCO 2022: The Atlantis Trial - maintenance cabozantinib in bladder cancer
|
Jun 03, 2022 |
|
Episode 172: ASCO 2022: Adjuvant everolimus in renal cancer
|
Jun 03, 2022 |
|
Episode 171: Antibody drug conjugates in bladder cancer: managing adverse effects
|
May 23, 2022 |
|
Episode 170: APCCC Meeting Summary
|
May 16, 2022 |
|
Episode 169: The Uromigos Paper of the Month - Novel neoadjuvant approaches in UC
|
May 09, 2022 |
|
Episode 168: Mechanisms of response to PD1 therapy in renal cancer
|
May 02, 2022 |
|
Episode 167: Highlights from EIKCS oral session
|
Apr 22, 2022 |
|
Episode 166: Prostate cancer debate: doublet vs triplet first line therapy
|
Apr 18, 2022 |
|
Episode 165: Paper of the Month - ENZAMET quality of life data
|
Apr 06, 2022 |
|
Episode 164: Paper of the Month - what can we learn from R3 ipilimumab/nivolumab in gastric cancer
|
Apr 01, 2022 |
|
Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer
|
Mar 21, 2022 |
|
Episode 162: Debate - Adjuvant nivolumab for bladder cancer
|
Mar 14, 2022 |
|
Episode 161: Platinum eligibility in urothelial cancer
|
Mar 07, 2022 |
|
Episode 160: APCCC - PMSA PET as a diagnostic
|
Feb 28, 2022 |
|
Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer
|
Feb 19, 2022 |
|
Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer
|
Feb 19, 2022 |
|
Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer
|
Feb 18, 2022 |
|
Episode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancer
|
Feb 18, 2022 |
|
Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC
|
Feb 17, 2022 |
|
Episode 155: ASCO GU 2022 ARASENS trial of darolutamide plus chemo vs chemo alone in hormone sensitive advanced prostate cancer
|
Feb 17, 2022 |
|
Episode 153: Overview of PARP inhibition in prostate cancer
|
Feb 10, 2022 |
|
Episode 152: The Uromigos Paper of the Month - Zr-Pembrolizumab PET Imaging
|
Feb 07, 2022 |
|
Episode 151: Bladder Cancer ESMO Guidelines update
|
Jan 31, 2022 |
|
Episode 150: Comparing the quality of life data in renal trials
|
Jan 24, 2022 |
|
Episode 149: Treatment-free survival for ipilimumab and nivolumab
|
Dec 28, 2021 |
|
Episode 148: The Uromigos Paper of the Month - Stereotactic radiotherapy for advanced renal cancer
|
Dec 21, 2021 |
|
Episode 147: Renal Cancer Christmas Special
|
Dec 17, 2021 |
|
Episode 146: Bladder Cancer Christmas Special
|
Dec 13, 2021 |
|
Episode 145: Prostate Cancer Christmas Special
|
Dec 06, 2021 |
|
Episode 144: Pembrolizumab for bladder cancer
|
Dec 02, 2021 |
|
Episode 143: The Uromigos Paper of the Month - Determinants of anti- PD-1 response and resistance in clear cell renal cell carcinoma
|
Nov 17, 2021 |
|
Episode 142: Un resumen de la reciente reunión de Uromigos en Canarias
|
Nov 13, 2021 |
|
Episode 141: Movember - Past, Present and Future
|
Nov 05, 2021 |
|
Episode 140: What is the role of ipilimumab in renal cancer?
|
Oct 29, 2021 |
|
Episode 139: The Uromigos Paper of the Month - Talazoparib in biomarker positive prostate cancer
|
Oct 27, 2021 |
|
Episode 138: Renal Cancer ESMO Guidelines Update
|
Oct 22, 2021 |
|
Episode 137: ESMO 2021: PEACE1 overall survival in prostate cancer
|
Sep 19, 2021 |
|
Episode 136: ESMO 2021: STAMPEDE Abiraterone for high-risk non-metastatic prostate cancer
|
Sep 19, 2021 |
|
Episode 135: ESMO 2021: The STAR Study
|
Sep 19, 2021 |
|
Episode 134: ESMO 2021: The PRISM Study
|
Sep 19, 2021 |
|
Episode 133: ESMO 2021: Cabozantinib and atezolizumab in prostate cancer
|
Sep 18, 2021 |
|
Episode 132: ESMO 2021: Pembro + sEphB4-HAS in bladder cancer
|
Sep 17, 2021 |
|
Episode 131: ESMO 2021: The NORSE Study - Erdafitinib vs Erdafitinib/Cetrelimab
|
Sep 17, 2021 |
|
Episode 130: Larry Einhorn - The Uromigos Legends in GU Cancer series
|
Sep 06, 2021 |
|
Episode 129: Phil Kantoff - The Uromigos Legends in GU Cancer series
|
Sep 02, 2021 |
|
Episode 128: APCCC - PSA relapse post prostatectomy
|
Aug 31, 2021 |
|
Episode 127: APCCC - Adjuvant radiotherapy post prostatectomy
|
Aug 31, 2021 |
|
Episode 126: APCCC - germ line testing and molecular testing in prostate cancer
|
Aug 31, 2021 |
|
Episode 125: The Uromigos Paper of the Month - MRI screening for prostate cancer
|
Aug 27, 2021 |
|
Episode 124: Dean Bajorin - The Uromigos Legends in GU Cancer series
|
Aug 23, 2021 |
|
Episode 123: Maha Hussain - The Uromigos Legends in GU Cancer series
|
Aug 20, 2021 |
|
Episode 122: Nick Vogelzang - The Uromigos Legends in GU Cancer series
|
Aug 16, 2021 |
|
Episode 121: Conflicts of Interest with the podcasts
|
Aug 04, 2021 |
|
Episode 119: EAU - Surgery in urothelial cancer
|
Jul 23, 2021 |
|
Episode 118: Prostate cancer highlights at EAU
|
Jul 20, 2021 |
|
Episode 117: PD1/VEGF adverse event management in renal cancer
|
Jul 20, 2021 |
|
Episode 116: Renal cancer surgery controversies at EAU
|
Jul 14, 2021 |
|
Episode 112: Genomic classifier of high risk African American men with prostate cancer identifying a high-risk population
|
Jul 05, 2021 |
|
Episode 115: Triplet therapy for 1st line metastatic prostate cancer
|
Jul 01, 2021 |
|
Episode 114: Radionucleotides in prostate cancer
|
Jun 18, 2021 |
|
Episode 113: ASCO 2021 Enazlutamide +/- Radium-223
|
Jun 18, 2021 |
|
Episode 111: The randomised phase 3 CANTATA in metastatic renal cancer
|
Jun 08, 2021 |
|
Episode 110: PEACE1 - Triplet therapy in prostate cancer
|
Jun 08, 2021 |
|
Episode 109: Adjuvant pembrolizumab in renal cancer
|
Jun 07, 2021 |
|
Episode 108: Peter O'Donnell gives five year follow-up data on front line pembrolizumab in urothelial cancer
|
Jun 07, 2021 |
|
Episode 107: ASCO 2021: Neoadjuvant chemo/nivolumab as bladder sparing
|
Jun 07, 2021 |
|
Episode 106: Summary of the three bladder sparing neoadjuvant trials at ASCO 2021
|
Jun 07, 2021 |
|
Episode 105: A Phase 2 study of novel immune combinations (ICOS) in bladder cancer
|
Jun 07, 2021 |
|
Episode 104: Plenary Session 177lu-PSMA-617 in Prostate Cancer
|
Jun 06, 2021 |
|
Episode 103: Targeting the microbiome to increase the activity of immune therapy in renal cancer
|
Jun 06, 2021 |
|
Episode 102: Adjuvant therapy in melanoma - how it will help inform the renal community
|
May 28, 2021 |
|
Episode 101: The Uromigos Paper of the Month - Belzutifan in renal cancer
|
May 26, 2021 |
|
Episode 100: The Uromigos 100th Podcast - Looking to the Future
|
May 21, 2021 |
|
Episode 99: Navigating social media from a patients' perspective
|
May 19, 2021 |
|
Episode 98: Bladder cancer from a patient perspective
|
May 19, 2021 |
|
Episode 97: Sacituzumab Govitecan in Bladder Cancer
|
May 04, 2021 |
|
Episode 96: ODAC Bladder Cancer Accelerated Approval Meetings with Andrea Apolo
|
Apr 28, 2021 |
|
Episode 95: ODAC Overview and Bladder Accelerated Approval Meetings with Jorge Garcia
|
Apr 28, 2021 |
|
Episode 94: EIKCS Summary of Day 1
|
Apr 23, 2021 |
|
Episode 93: The Uromigos Paper of the Month - A new risk classification for germ cell cancer
|
Apr 14, 2021 |
|
Episode 92: Second line therapy in advanced RCC
|
Apr 09, 2021 |
|
Episode 91: The Uromigos Paper of the Month - Adjuvant atezolizumab in bladder cancer
|
Mar 26, 2021 |
|
Episode 90: The Uromigos Podcast with QOL Expert David Cella
|
Mar 12, 2021 |
|
Episode 89: The Uromigos Paper of the Month - Pembrolizumab in clear cell and non-clear cell renal cancer
|
Mar 04, 2021 |
|
Episode 88: Career Development in Academic Oncology Part 3 - Walter Stadler
|
Feb 26, 2021 |
|
Episode 87: Career Development in Academic Oncology Part 2 - Monty Pal
|
Feb 26, 2021 |
|
Episode 86: Career Development in Academic Oncology Part 1 - Moshe Ornstein
|
Feb 26, 2021 |
|
Episode 85: The CLEAR Trial
|
Feb 14, 2021 |
|
Episode 84: Prostate cancer highlights from ASCO #GU21 with Chris Sweeney
|
Feb 13, 2021 |
|
Episode 82: Which is the best VEGF/immune combination for first line metastatic renal cancer?
|
Feb 13, 2021 |
|
Episode 83: Is cabozantinib the new standard of care in papillary renal cancer?
|
Feb 13, 2021 |
|
Episode 81: Noah Hahn discusses front line cisplatin-ineligible PD-L1 data from 361 and 130
|
Feb 13, 2021 |
|
Episode 80: Results for Darolutamide in non-metastatic CRPC - the Aramis trial
|
Feb 13, 2021 |
|
Episode 79: Adjuvant nivolumab in operable urothelial cancer
|
Feb 13, 2021 |
|
Episode 78: Enfortumab Vedotin Special: EV301 randomised trial and EV201 in urothelial cancer
|
Feb 12, 2021 |
|
Episode 77: The Uromigos Paper of the Month - Nadofaragene for BCG unresponsive NMIBC
|
Feb 06, 2021 |
|
Episode 76: Tom Hutson discusses lenvatinib and everolimus
|
Jan 22, 2021 |
|
Episode 75: The Uromigos meet APCCC - bone health and bone disease in prostate cancer with Bertrand Tombal
|
Jan 14, 2021 |
|
Episode 74: The Uromigos meet APCCC Round 2: First line treatment - low vs high volume; chemo vs abi/enza
|
Jan 11, 2021 |
|
Episode 73: The Uromigos meet APCCC in a discussion on oligometastatic prostate cancer @APCCC_Lugano
|
Jan 08, 2021 |
|
Episode 72: Uromigos Christmas Special - Renal cancer year in review
|
Dec 21, 2020 |
|
Episode 71: Bladder Cancer Uromigos Christmas Special with Matt Galsky
|
Dec 18, 2020 |
|
Episode 70: The Uromigos Prostate Cancer Christmas Special with Chuck Ryan
|
Dec 11, 2020 |
|
Episode 69: Testis Cancer Christmas Special: 2020 year in review
|
Dec 09, 2020 |
|
Episode 68: Uromigos Paper of the Month - a molecular classification of renal cancer in Cancer Cell
|
Dec 08, 2020 |
|
Episode 67: The Third Uromigos Debate - PD1/VEGF vs PD1/CTLA4 for front line renal cancer
|
Nov 17, 2020 |
|
Episode 66: Uromigos Paper of the Month - Two papers in Nature Medicine on neoadjuvant immune combinations in bladder cancer
|
Nov 09, 2020 |
|
Episode 65: Review of the International Kidney Cancer Symposium
|
Nov 02, 2020 |
|
Episode 64: The Second Uromigos debate with Nobel Laureate Bill Kaelin on new biomarker vs new drugs in RCC
|
Oct 28, 2020 |
|
Episode 63: The First Uromigos Debate: front line immune therapy vs maintenance avelumab in bladder cancer
|
Oct 09, 2020 |
|
Episode 62: James Eastham's Uromigos Paper of the Month - Prostatectomy +/- Neoadjuvant Chemo
|
Oct 06, 2020 |
|
Episode 61: Nick James discusses the latest update of the STAMPEDE study
|
Sep 21, 2020 |
|
Episode 60: Cora Sternberg discusses AMG 160 - a bispecific antibody in prostate cancer
|
Sep 21, 2020 |
|
Episode 59: Ipatercertib in biomarker positive castrate resistant prostate cancer
|
Sep 20, 2020 |
|
Episode 58: Brilliant ESMO discussant Richard Cathomas talks to Brian and Tom about the meaning of DANUBE and KN362
|
Sep 19, 2020 |
|
Episode 57: Toni Choueiri - cabo & nivo vs sunitinib in metastatic clear cell renal cancer
|
Sep 19, 2020 |
|
Episode 56: Matt Galsky and Tom Powles discuss ESMO 2020 immune therapy data in bladder cancer
|
Sep 19, 2020 |
|
Episode 55: The Uromigos Paper of the Month - Cabozantinib in Bladder Cancer by Dr. Andrea Apolo
|
Aug 31, 2020 |
|
Episode 54: Biomarkers in prostate cancer with Chris Sweeney
|
Jul 24, 2020 |
|
Episode 53: Still in Boston - biomarkers in bladder cancer
|
Jul 24, 2020 |
|
Episode 52: The Final Stop - Boston: David McDermott discusses biomarkers in renal cancer in the era of immune therapy
|
Jul 24, 2020 |
|
Episode 51: The Uromigos World Tour is in Norway with Jan Oldenburg - discussing key topics in testis cancer
|
Jul 18, 2020 |
|
Episode 50: The Uromigos World Tour in London with renal cancer surgery
|
Jul 15, 2020 |
|
Episode 49: The Tour remains in Germany with Oliver Grimm and renal cancer
|
Jul 14, 2020 |
|
Episode 48: ...and then Germany - Jürgen Gschwend discusses cystectomy for urothelial cancer
|
Jul 10, 2020 |
|
Episode 46: The Uromigos World Tour in Spain discussing SOGUG and Renal Cancer with Cristina Suarez
|
Jul 09, 2020 |
|
Episode 45: The Uromigos World Tour arrives in Japan
|
Jul 03, 2020 |
|
Episode 44: The Uromigos World Tour in Australia - Talking with Ian Davis about prostate cancer and ANZUP
|
Jul 03, 2020 |
|
Episode 43: The Uromigos World Tour in Singapore with Ravi Kanesvaran
|
Jun 29, 2020 |
|
Episode 42: The Uromigos in Argentina
|
Jun 28, 2020 |
|
Episode 41: The Uromigos World Tour lands in Brazil - Fernando Maluf talks about prostate cancer and recent research in Brazil
|
Jun 25, 2020 |
|
Episode 40: The Uromigos World Tour moves to France - Bernard Escudier discusses 2nd line therapy in renal cancer and Tivozanib
|
Jun 22, 2020 |
|
Episode 39: The Uromigos World Tour - Renal Cancer and IMDC Risk with Danny Heng in Calgary
|
Jun 18, 2020 |
|
Episode 38: The Uromigos Virtual World Tour - starting in Vancouver with Atezolizumab in NMIBC
|
Jun 16, 2020 |
|
Episode 37: Regoratinib (FGFR inhibitor) and Atezolizumab in UC with Jonathan Rosenberg
|
Jun 01, 2020 |
|
Episode 36: Dr. Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations
|
Jun 01, 2020 |
|
Episode 35: Maintenance Avelumab in Bladder Cancer (LBA1)
|
May 31, 2020 |
|
Episode 34: Savolitinib in Renal Papillary Cancer - A Major Breakthrough?
|
May 30, 2020 |
|
Episode 33: Adjuvant Atezolizumab in Urothelial Cancer
|
May 29, 2020 |
|
Episode 32: A Phase 2 Study of PSMA PET in Prostate Cancer with Thomas Hope from ASCO 2020
|
May 29, 2020 |
|
Episode 31: A Phase 2 Study of Nivolumab with the Addition of Ipilimumab Upon Progression in Renal Cancer
|
May 29, 2020 |
|
Episode 30: Update on Axitinib plus Pembrolizumab in Renal Cancer (KEYNOTE 426)
|
May 29, 2020 |
|
Episode 29: PSMA PET at ASCO 2020 with Mike Morris
|
May 29, 2020 |
|
Episode 28: Targeting VHL Syndrome Renal Cancer with a HIF Inhibitor - A Game Changer
|
May 29, 2020 |
|
Episode 27: COVID-19 in > 1000 Cancer Patients with Jeremy Warner (CCC-19)
|
May 29, 2020 |
|
Episode 26: Joaquim Bellmunt and Muscle Invasive Bladder Cancer prior to ASCO 2020
|
May 19, 2020 |
|
Episode 25: Dr. Tian Zhang discusses first line treatment for renal cancer and the PDIGREE Trial
|
May 19, 2020 |
|
Episode 24: A Study of COVID-19 in Lung Cancer Shows High Mortality
|
Apr 28, 2020 |
|
Episode 23: Atezolizumab and Enzalutamide versus Enzalutamide Prostate Cancer
|
Apr 28, 2020 |
|
Episode 22: COVID-19 and Cardiovascular Disease
|
Apr 22, 2020 |
|
Episode 21: Treating cancer patients over the next year in the era of COVID-19
|
Apr 15, 2020 |
|
Episode 20: Treating GU Cancer Patients with acute COVID-19 Infection
|
Apr 15, 2020 |
|
Episode 19: Professor Monty Pal discusses the treatment of non-clear cell renal cancer
|
Apr 15, 2020 |
|
Episode 18: COVID-19: Addressing Renal Cancer Patients’ Concerns
|
Apr 06, 2020 |
|
Episode 17: Dr. Toni Choueiri discusses cancer trials and meetings during COVID-19
|
Apr 02, 2020 |
|
Episode 16: Treatments and Trials for COVID-19
|
Mar 31, 2020 |
|
Episode 15: COVID-19 and Bladder Cancer Surgery
|
Mar 28, 2020 |
|
Episode 14: A Discussion about Tocilizumab and COVID-19 with Dr. Nick Mark from Seattle
|
Mar 24, 2020 |
|
Episode 13: COVID-19 and Hydroxychloroquinine Existing Data and Ongoing Trials
|
Mar 23, 2020 |
|
Episode 12: COVID-19 in Cancer Patients - The Seattle Experience
|
Mar 20, 2020 |
|
Episode 11: COVID-19 and Immune Checkpoint Inhibitors for the Treatment of Cancer
|
Mar 16, 2020 |
|
Episode 10: COVID-19 and Renal Cancer: A Patient's Perspective
|
Mar 16, 2020 |
|
Episode 9: COVID-19 and Cancer: An International Perspective
|
Mar 16, 2020 |
|
Episode 8: COVID-19 and Cancer Patients
|
Mar 13, 2020 |
|
Episode 7: The First Uromigos Prostate Cancer Podcast
|
Feb 27, 2020 |
|
Episode 6: Urothelial Cancer Highlights from ASCO GU 2020
|
Feb 26, 2020 |
|
Episode 5: Renal Highlights from ASCO GU 2020
|
Feb 24, 2020 |
|
Episode 4: Treatment Choices in Front Line Advanced Renal Cancer
|
Feb 11, 2020 |
|
Episode 1: Introduction to Uromigos Podcasts
|
Feb 11, 2020 |
|
Episode 2: The Current role of IO in Front-line Advanced Urothelial Cancer
|
Feb 11, 2020 |
|
Episode 3: Pembrolizumab in Non-Muscle Invasive Bladder Cancer
|
Feb 11, 2020 |